![]() ![]() SEEQ Mobile Cardiac Telemetry (MCT) provides continuous, near-real-time ECG (electrocardiogram) monitoring of a patient for up to 30 days. Medtronic believes the properties, features and benefits of this technology may be of great interest to others wishing to offer an FDA approved, turnkey mobile cardiac monitoring and solution to their client base. The SEEQ MCT business achieved $10M in sales during FY 2017 before being discontinued in May 2018. Medtronic acquired Corventis in May 2014, rebranding the Nuvant MCT as SEEQ MCT. ![]() The Nuvant Mobile Cardiac Telemetry System which uses the Piix sensor, was cleared by the FDA in 2010. ![]() The underlying sensor technology, Piix, received FDA approval in 2009 for detect signs of heart failure by monitoring heart rate, respiratory rate, temperature, fluid levels and patient activity. The SEEQ product (originally named Nuvant) was conceived, designed, developed and launched by Corventis, Inc. On behalf of our client, Medtronic, yet2 announces that a SEEQ Mobile Cardiac Telemetry Patch and Bluetooth/cellular automatic data collection and transmission technology, and related business assets are available for acquisition. This device can be expanded for use in remote patient monitoring – tracking and reporting in near real-time: heart rate, respiratory rate, fluid levels, body temperature, and patient activity. This FDA approved, CE marked, water-resistant patch provides near real-time continuous arrhythmia detection for up to 7.5 days without having to replace or recharge the battery. The SEEQ™ MCT (mobile cardiac telemetry) System is an external heart monitor that can be prescribed for up to 30 days to help detect and diagnose the cause of irregular heartbeats in patients. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |